At a glance
ClinicalIndex Comparison RecordN/ACompleted· 735 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in France
In Brief
An observational study for Chronic Hepatitis C. Completed, enrolled 735 participants across 70 sites.
Detailed Summary
This study seeks to determine the effectiveness of the interferon-free ABBVIE REGIMEN ± ribavirin (RBV) in participants with chronic hepatitis C (CHC) virus in clinical practices across France.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 2015
Enrollment StartDec 2015
Primary CompletionMar 2018
TodayJul 2026
First PostedDec 2, 2015
Enrollment StartDec 15, 2015
Primary CompletionMar 29, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.6 years ago